Demographics, pretreatment characteristics, and treatment schedule in 24 patients
| Characteristics . | Data . |
|---|---|
| Male, % | 50 |
| Median age, y (range) | 59 (41-82) |
| IgG/IgA/IgD/light chain only, % | 29/25/4/42 |
| No. of prior therapies | |
| Median (range) | 2 (0-6) |
| None, no. (%) | 1 (4) |
| 1, no. (%) | 4 (17) |
| 2 or 3, no. (%) | 12 (50) |
| 4 or more, no. (%) | 3 (13) |
| Unknown, no. (%) | 4 (17) |
| Serum creatinine level | |
| Median, mg/dL (range) | 6.8 (3.1-12.8) |
| More than 2 mg/dL, no. (%) | 22 (92) |
| More than 6 mg/dL, no. (%) | 15 (63) |
| Unknown, no. (%) | 2 (8) |
| Median hemoglobin level,* g/dL (range) | 10.2 (7.4-15.3) |
| Median platelet count,* × 109/L (range) | 186 (25-369) |
| Etiology of renal failure, no. (%) | |
| Progressive MM | 14 (58) |
| Amyloidosis | 2 (8) |
| Renal cortical atrophy | 1 (4) |
| Unknown | 7 (29) |
| Bortezomib treatment, no. (%)† | |
| Alone | 2 (8) |
| Plus dexamethasone | 6 (25) |
| Plus dexamethasone and thalidomide | 4 (17) |
| Plus liposomal doxorubicin and thalidomide† | 7 (29) |
| Other combinations‡ | 4 (17) |
| Not specified | 1 (4) |
| Bortezomib starting dose, no. (%) | |
| Less than 1.0 mg/m2 | 1 (4) |
| 1.0 mg/m2 | 3 (13) |
| 1.3 mg/m2 | 20 (83) |
| Median no. of cycles of bortezomib (range) | 5 (2-20) |
| Timing of treatment relative to dialysis, no. (%) | |
| Before dialysis | 1 (4) |
| During dialysis | 1 (4) |
| After dialysis§ | 20 (83) |
| Not reported | 1 (4) |
| No dialysis | 1 (4) |
| Characteristics . | Data . |
|---|---|
| Male, % | 50 |
| Median age, y (range) | 59 (41-82) |
| IgG/IgA/IgD/light chain only, % | 29/25/4/42 |
| No. of prior therapies | |
| Median (range) | 2 (0-6) |
| None, no. (%) | 1 (4) |
| 1, no. (%) | 4 (17) |
| 2 or 3, no. (%) | 12 (50) |
| 4 or more, no. (%) | 3 (13) |
| Unknown, no. (%) | 4 (17) |
| Serum creatinine level | |
| Median, mg/dL (range) | 6.8 (3.1-12.8) |
| More than 2 mg/dL, no. (%) | 22 (92) |
| More than 6 mg/dL, no. (%) | 15 (63) |
| Unknown, no. (%) | 2 (8) |
| Median hemoglobin level,* g/dL (range) | 10.2 (7.4-15.3) |
| Median platelet count,* × 109/L (range) | 186 (25-369) |
| Etiology of renal failure, no. (%) | |
| Progressive MM | 14 (58) |
| Amyloidosis | 2 (8) |
| Renal cortical atrophy | 1 (4) |
| Unknown | 7 (29) |
| Bortezomib treatment, no. (%)† | |
| Alone | 2 (8) |
| Plus dexamethasone | 6 (25) |
| Plus dexamethasone and thalidomide | 4 (17) |
| Plus liposomal doxorubicin and thalidomide† | 7 (29) |
| Other combinations‡ | 4 (17) |
| Not specified | 1 (4) |
| Bortezomib starting dose, no. (%) | |
| Less than 1.0 mg/m2 | 1 (4) |
| 1.0 mg/m2 | 3 (13) |
| 1.3 mg/m2 | 20 (83) |
| Median no. of cycles of bortezomib (range) | 5 (2-20) |
| Timing of treatment relative to dialysis, no. (%) | |
| Before dialysis | 1 (4) |
| During dialysis | 1 (4) |
| After dialysis§ | 20 (83) |
| Not reported | 1 (4) |
| No dialysis | 1 (4) |
Data available from 22 patients.
Bortezomib was administered using the standard dose schedule (days 1, 4, 8, and 11 every 3 weeks) except in 7 patients who received an alternative schedule of bortezomib (days 1, 4, 15, and 18 every 4 weeks).
Other regimens included combinations with cyclophosphamide, doxorubicin, thalidomide, dexamethasone, and prednisone.
One patient received treatment both after and before the dialysis procedure on separate hospital visits.